Article
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.
Blood - 4 Mar 2021
Corre Jill, Perrot Aurore, Caillot Denis, Belhadj Karim, Hulin Cyrille, Leleu Xavier, Mohty Mohamad, Facon Thierry, Buisson Laure, Do Souto Laura, Lannes Romain, Dufrechou Stephanie, Prade Naïs, Orsini-Piocelle Frederique, Voillat Laurent, Jaccard Arnaud, Karlin Lionel, Macro Margaret, Brechignac Sabine, Dib Mamoun, Sanhes Laurence, Fontan Jean, Clement-Filliatre Lauriane, Marolleau Jean-Pierre, Minvielle Stephane, Moreau Philippe, Avet-Loiseau Hervé
Abstract excerpt
Despite tremendous improvements in the outcome of patients with multiple myeloma in the past decade, high-risk patients have not benefited from the approval of novel drugs. The most important prognostic factor is the loss of parts of the short arm of chromosome 17, known as deletion 17p (del(17p)). A recent publication (on a small number of patients) suggested that these patients are at very high-risk only if...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.